Literature DB >> 23238876

Concordance of the late night salivary cortisol in patients with Cushing's syndrome and elevated urine-free cortisol.

Suhail A R Doi1, Justin Clark, Anthony W Russell.   

Abstract

The concordance of the late night salivary cortisol (LNSC) results with the 24-h urine-free cortisol (UFC) results in the biochemical screening for Cushing's syndrome is unknown. We investigated this in a population of Cushing's syndrome subjects. We used meta-analytic methods to pool proportions of LNSC-positive subjects from diagnostic evaluations of Cushing's syndrome subjects where both tests were performed and the UFC was elevated (any level). Cushing's syndrome was confirmed in all subjects by two out of three conventional tests. LNSC was collected between 22:00 to 24:00 h and measured around the same time period as the UFC. Minimum cutoffs of ≥4 and ≥10 nmol/L were used to determine concordance with the UFC and studies were limited to those that used radioimmunoassays or electrochemiluminiscence immunoassays for LNSC. The concordance of LNSC ≥4 nmol/L was 97 % (95 % CI 95-99 %) and studies were homogeneous. With LNSC ≥10 nmol/L, there was heterogeneity and two groups were discernible with a pooled concordance of 69 % (95 % CI 60-77 %) and 95 % (95 % CI 92-97 %). Within these sub-groups, studies were homogeneous and there was no difference between them in collection methods, assays used, geographic location, year of publication, or the quality of the underlying studies. The LNSC at a very specific cutoff detects at best 95 % of cases and at worst 69 % of cases of Cushing's syndrome that are UFC positive. The two tests become equivalent at the more sensitive cutoff (>4 nmol/L). We conclude that, given its many benefits and the currently documented equivalence to the UFC, the LNSC should replace the conventional 24-h UFC as the frontline test when screening for Cushing's syndrome.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23238876     DOI: 10.1007/s12020-012-9855-0

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  31 in total

1.  Determination of cortisol in human saliva using liquid chromatography-electrospray tandem mass spectrometry.

Authors:  Bo A G Jönsson; Birgitta Malmberg; Asa Amilon; Anne Helene Garde; Palle Orbaek
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2003-01-25       Impact factor: 3.205

2.  Meta-analysis of heterogeneous clinical trials: an empirical example.

Authors:  Suhail A R Doi; Jan J Barendregt; Ellen L Mozurkewich
Journal:  Contemp Clin Trials       Date:  2010-12-13       Impact factor: 2.226

Review 3.  Accuracy of diagnostic tests for Cushing's syndrome: a systematic review and metaanalyses.

Authors:  Mohamed B Elamin; M Hassan Murad; Rebecca Mullan; Dana Erickson; Katherine Harris; Sarah Nadeem; Robert Ennis; Patricia J Erwin; Victor M Montori
Journal:  J Clin Endocrinol Metab       Date:  2008-03-11       Impact factor: 5.958

Review 4.  Measurement of salivary cortisol in 2012 - laboratory techniques and clinical indications.

Authors:  Warrick J Inder; Goce Dimeski; Anthony Russell
Journal:  Clin Endocrinol (Oxf)       Date:  2012-11       Impact factor: 3.478

5.  Reproducibility of nighttime salivary cortisol and its use in the diagnosis of hypercortisolism compared with urinary free cortisol and overnight dexamethasone suppression test.

Authors:  Alexander Viardot; Peter Huber; Jardena J Puder; Henryk Zulewski; Ulrich Keller; Beat Müller
Journal:  J Clin Endocrinol Metab       Date:  2005-07-12       Impact factor: 5.958

6.  Late-night salivary cortisol as a screening test for Cushing's syndrome.

Authors:  H Raff; J L Raff; J W Findling
Journal:  J Clin Endocrinol Metab       Date:  1998-08       Impact factor: 5.958

7.  Late-night salivary cortisol for the diagnosis of Cushing syndrome: a meta-analysis.

Authors:  Ty Carroll; Hershel Raff; James W Findling
Journal:  Endocr Pract       Date:  2009 May-Jun       Impact factor: 3.443

8.  Midnight salivary cortisol determination for assessing the outcome of transsphenoidal surgery in Cushing's disease.

Authors:  Carmen A Carrasco; Joël Coste; Laurence Guignat; Lionel Groussin; Marie Annick Dugué; Stéphane Gaillard; Xavier Bertagna; Jérôme Bertherat
Journal:  J Clin Endocrinol Metab       Date:  2008-08-26       Impact factor: 5.958

9.  Late-night salivary cortisol for diagnosis of overt and subclinical Cushing's syndrome in hospitalized and ambulatory patients.

Authors:  Marie-Laure Nunes; Stéphanie Vattaut; Jean-Benoît Corcuff; Alexandre Rault; Hugues Loiseau; Blandine Gatta; Nathalie Valli; Luc Letenneur; Antoine Tabarin
Journal:  J Clin Endocrinol Metab       Date:  2008-11-11       Impact factor: 5.958

10.  Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies.

Authors:  Penny F Whiting; Marie E Weswood; Anne W S Rutjes; Johannes B Reitsma; Patrick N M Bossuyt; Jos Kleijnen
Journal:  BMC Med Res Methodol       Date:  2006-03-06       Impact factor: 4.615

View more
  5 in total

1.  The role of an acute pasireotide suppression test in predicting response to treatment in patients with Cushing's disease: findings from a pilot study.

Authors:  L Trementino; M Zilio; G Marcelli; G Michetti; M Barbot; F Ceccato; M Boscaro; C Scaroni; G Arnaldi
Journal:  Endocrine       Date:  2014-12-11       Impact factor: 3.633

Review 2.  Managing Cushing's disease: the state of the art.

Authors:  Annamaria Colao; Marco Boscaro; Diego Ferone; Felipe F Casanueva
Journal:  Endocrine       Date:  2014-01-11       Impact factor: 3.633

3.  Saliva versus serum cortisol to identify subclinical hypercortisolism in adrenal incidentalomas: simplicity versus accuracy.

Authors:  M Vieira-Correa; R B Giorgi; K C Oliveira; L F Hayashi; F A Costa-Barbosa; C E Kater
Journal:  J Endocrinol Invest       Date:  2019-08-27       Impact factor: 4.256

Review 4.  Harmful effects of functional hypercortisolism: a working hypothesis.

Authors:  Giacomo Tirabassi; Marco Boscaro; Giorgio Arnaldi
Journal:  Endocrine       Date:  2013-11-27       Impact factor: 3.633

5.  Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing's disease: 12-month, Phase III pasireotide study.

Authors:  James W Findling; Maria Fleseriu; John Newell-Price; Stephan Petersenn; Rosario Pivonello; Albert Kandra; Alberto M Pedroncelli; Beverly M K Biller
Journal:  Endocrine       Date:  2016-05-21       Impact factor: 3.633

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.